ENDRA Life Sciences Inc. Warrants
NDRAW
NDRAW was delisted on the 12th of May, 2022.
2 hedge funds and large institutions have $0 invested in ENDRA Life Sciences Inc. Warrants in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
100% more funds holding
Funds holding: 1 → 2 (+1)
100% less capital invested
Capital invested by funds: $2K → $0 (-$2K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$36 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.58K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| – | -$2.58K | -7,100 | -98% |
|
|
2
Bank of America
Charlotte,
North Carolina
| – | +$36 | +100 | New |
|
NDRAW Hedge Fund Activity: Q4 2019 in Review
2 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in ENDRA Life Sciences Inc. Warrants (NDRAW) for Q4 2019, worth a combined $0 — down 100% from $2K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NDRAW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $36. The largest seller was UBS Group, cutting an estimated $2.58K.
- 2 institutional investors held ENDRA Life Sciences Inc. Warrants (NDRAW) as of Q4 2019, up from 1 in Q3 2019.
- Funds reported $0 of ENDRA Life Sciences Inc. Warrants stock for Q4 2019, down 100% quarter-over-quarter.
- 1 fund opened new ENDRA Life Sciences Inc. Warrants positions in Q4 2019 and 0 closed out, a net change of +1 holder.
- The largest ENDRA Life Sciences Inc. Warrants buyer in Q4 2019 was Bank of America, an estimated $36 added.
- The largest ENDRA Life Sciences Inc. Warrants seller in Q4 2019 was UBS Group, an estimated $2.58K sold.
Based on aggregated 13F filings for Q4 2019.